Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.


Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?


Please Try Again {{ error }}

Send my password

An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Stock Quote Today & Recent News Nexalin Technology Inc NXL

Nexalin Technology, Inc. is engaged in designing and developing neurostimulation products for mental health epidemic. The Company has developed an easy-to-administer medical device, Generation 1 or Gen-1 that utilizes bioelectronic medical technology to treat anxiety and insomnia, without the need for drugs or psychotherapy. It is also designing clinical trials for the use of Gen-2 for the... see more
< Previous
Next >

Current News (NDAQ:NXL)

Nexalin Technology Reports Results of Clinical Study Supporting the Therapeutic Benefits of its Gen-2, 15 Milliamp Neurostimulation Device in Treating Migraine Headaches and Related Symptoms

GlobeNewswire August 7, 2023

Nexalin's CEO Mark White to be Interviewed Live on "The Big Biz Show" Today at 3PM Eastern Time

GlobeNewswire August 3, 2023

Nexalin Technology Announces New Public Sector Division to Capitalize on Opportunities to Serve U.S. Government Agencies

GlobeNewswire July 26, 2023

Nexalin Technology Announces Abstract Accepted for Presentation at 2023 Military Health System Research Symposium Validating the Potential of its Non-Invasive, Frequency-Based Deep-Brain Stimulation Device for the Treatment of Mild Traumatic Brain Injury

GlobeNewswire July 10, 2023

Nexalin Technology, Inc. and Wider Come Limited Announce Joint Venture Agreement to Advance Commercialization of Nexalin's tACS Devices in the Asia Pacific Region

GlobeNewswire June 1, 2023

Nexalin Technology Provides 2022 Year-End Business Update

GlobeNewswire March 27, 2023

Nexalin Technology Appoints Medical Device Veteran Michael Nketiah as Senior Vice President of Quality, Clinical and Regulatory

GlobeNewswire January 24, 2023

Nexalin Technology CEO Provides Letter to Shareholders

GlobeNewswire January 5, 2023

Nexalin Technology Announces Publication of a White Paper Validating its tACS Device for the Treatment of Generalized Anxiety Disorder

GlobeNewswire November 14, 2022

Opinion & Analysis (NDAQ:NXL)

No current opinion is available.

Bullboard Posts (NDAQ:NXL)